Emma Lawrence (née Fisher) 21.01.81 – 13.07.24 Everyone at METUPUK is incredibly saddened to hear that Emma Lawrence (née Fisher) has died at the age of 43. Emma was diagnosed
Emma Lawrence (née Fisher)
Could the next big drug for metastatic breast cancer patients be physical activity?
I have always participated in some kind of form of physical activity. I was a gymnast when I was young, loved the fact I could walk on my hands, do
Kit Dzeryn
Sadly our Kit @Diamondtrees11 died on Monday 7th May. Her husband Phillip contacted us with the tragic news. We didn’t meet Kit but she was an integral part of METUPUK
Bren Craggs – IN NAM Graduate Desert Challenge 2023
Back in the summer of 2022, our daughter’s partner, Bren, talked to me about the IN NAM Graduate Desert challenge that he had signed up to. When he explained what
GIVEACAR and why they support METUPUK
In September last year, one of our Trustees Louise Furneaux died from metastatic breast cancer. She was a valued member of METUPUK and was our most recently appointed trustee. She
“I’m definitely living. I’m not dying yet.”
Sandy Sexton, patient advocate for METUPUK, is campaigning in Scotland on behalf of secondary/metastatic Breast Cancer patients. In October last year, after 18 months of debilitating back pain, Sandy was
Feeling guilty FOR working. Feeling guilty for NOT working.
As a partner of someone with metastatic cancer, it can be very difficult to know what the right amount of paid work is to do. Sometimes it feels like I
LMD (Leptomeningeal Disease) and whole brain radiotherapy – Carole’s story
Do you remember what you were wearing on 1 December 2019? Probably not. I do though. I was wearing a blue Valencia Marathon t-shirt, an exhausted but elated perma-grin and
On the trail of a clinical trial (Kit’s story)
Clinical trials are essential for testing new treatments for metastatic breast cancer. For patients, they represent hope – the chance to get access to a new potential treatment before it
Abemaciclib – new treatment
Starting a new medication can be a daunting experience, especially if the medication is still fairly new to the market. Abemaciclib may not be a household name, but for those